Clinical trials - 12 News by Genmab for the biotechnology industry

Tip: You can further refine your news selection by departments.

Clinical trials - 12 News by Genmab for the biotechnology industry

Tip: You can further refine your news selection by departments.

Genmab provides insights into IgG4 antibodies

17-Sep-2007 - Genmab A/S announced its scientists have discovered the basis for the instability of human IgG4 antibodies underlying their biological role in the immune system. In pre-clinical studies, Genmab discovered that IgG4 antibodies are dynamic and unstable molecules that naturally exchange their ...

clinical trials allergies antibodies

Genmab's HuMax-HepC prevents Hepatitis C virus infection in animal models

23-May-2007 - Genmab A/S announced its fully human antibody HuMax-HepC(TM) prevented Hepatitis C virus (HCV) infection in a novel animal model. In the pre-clinical study, mice with a compromised immune system were transplanted with human liver cells (hepatocytes) and exposed to a mixture of patient-derived HCV ...

clinical trials hepatitis C hepatocytes

Genmab announces early results of ongoing HuMax-CD4 trials

12-Dec-2006 - Genmab A/S announced positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4® (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL). In the pivotal CTCL study, clinical response was shown in ...

clinical trials chemotherapy T cells

Genmab reaches first milestone in HuMax-TAC agreement with Serono

01-Mar-2006 - Genmab A/S announced it has delivered a HuMax-TAC cell line to Serono, marking the first milestone in the companies' development and commercialization agreement. The cell line could be used to manufacture HuMax-TAC for clinical trials. This milestone triggers a payment to Genmab of USD 1 ...

clinical trials cell lines milestone payments

Genmab receives patent for HuMax-HepC

07-Nov-2005 - Genmab A/S announced that a patent has been issued for HuMax®-HepC by the US Patent and Trademark Office. HuMax-HepC is a fully human antibody currently in pre-clinical development to prevent reinfection with the Hepatitis C Virus (HCV) after liver transplantation. HuMax-HepC binds to a common ...

clinical trials hepatitis C

Serono and Genmab annouce global development and commercialization agreement for HuMax-CD4

22-Aug-2005 - Serono and Genmab A/S announced an agreement under which Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-CD4. HuMax-CD4 is a fully human monoclonal antibody in development for the treatment of cutaneous and non-cutaneous T-cell lymphomas. It is ...

clinical trials food Japan

Genmab acquieres worldwide rights for HUMAX-CD4

05-Jul-2005 - Genmab A/S announced that it has licensed from Medarex, Inc. the European and Asian rights to utilize Medarex's UltiMAb® technology to develop and commercialize antibodies raised against the CD4 antigen, including HuMax-CD4(TM), a fully human antibody that Genmab currently has in Phase III ...

clinical trials antibodies Orphan Drug Designation

Serono and Genmab sign worldwide agreement to develop and commercialize Humax-TAC

04-May-2005 - Serono and Genmab A/S announced that they have signed an agreement under which Genmab grants Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC. The product is a fully human monoclonal antibody targeting the TAC antigen - also known as CD25, or the interleukin-2 ...

clinical trials antigens milestone payments

Genmab's HuMax-CD4 to treat lymphoma awarded Fast Track Status from FDA

24-Mar-2004 - Copenhagen. Genmab A/S announced that HuMax-CD4 has been designated a Fast Track Product by the US Food and Drug Administration (FDA). This designation covers patients with cutaneous T-cell lymphoma (CTCL) who have failed currently available therapy. This patient group includes those who are ...

clinical trials biologics Fast Track status

Genmab's HuMax-CD4 achieves positive interim results in extended Phase II studies for CTCL

19-Feb-2004 - Copenhagen, Denmark. Genmab A/S announced it will present data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65TH Annual Meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ...

clinical trials Denmark dermatology
Search all
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,246 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now